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Abstract
Opioid dependence is an increasing clinical and public 
health problem. Current pharmacotherapies have limited ef-
ficacy and cause serious side effects. Increasing bodies of 
evidences suggest the neuropeptide, oxytocin (OT), as a po-
tential treatment for drug abuse disorders. The current study 
was designed to evaluate the effect of OT on withdrawal, 
craving and anxiety scores, cortisol and dehydroepiandros-
terone sulphate (DHEAS) blood level in heroin-dependent 
male patients. This randomized, double-blind placebo-con-
trolled clinical trial was conducted on 58 males with opioid 
dependence by Abstinence Center of Addictive People in 
Iran. The participants were randomly allocated to receive in-
tranasal OT (single dose; 40 IU, n = 29) or placebo (n = 29). 
Heroine withdrawal, craving and anxiety scores were mea-
sured using the Opioid Withdrawal Scale, Visual Analogue 
Scale and (Desire for Drug Questionnaire), and Hamilton 
checklist respectively. The cortisol and DHEAS levels at base-
line and different post-intervention time were measured us-
ing a competitive immunoanalysis method. Acute OT ad-
ministration reduced craving and withdrawal scores but did 
not change anxiety significantly. Single dose of OT decreased 
the level of cortisol and improved the cortisol/DHEAS ratio 
in the heroin users during abstinence (p < 0.01). These results 
suggest that OT may be useful in the attenuation of craving, 
withdrawal symptom in heroin-dependent patients and 
might be considered a new potential treatment for heroin 
dependence where positive effects of OT on stress-related 
hormones may be involved in this effect of OT.
© 2019 S. Karger AG, Basel
Introduction
About 31 million people worldwide are affected by 
drug use disorders. According to WHO, roughly 450,000 
people died as a result of drug use in 2015. Opioids con-
tinued to cause the most harm, accounting for 76% of the 
deaths where drug use disorders were implicated. The re-
cent increase of opium production has resulted in an in-
crease in heroin use in many nations [1]. Heroin depen-
dence is a devastating, chronic psychiatric disorder. It is 
a maladaptive state associated with a withdrawal syn-
drome and intense craving. Heroin dependents experi-
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ence an extreme amount of stress for a long period of time 
after they stop drug abuse. Treatment strategies in drug 
dependence are usually aimed at achieving control of 
withdrawal syndromes and reducing relapse and craving. 
Several protocols of treatment are available for heroin de-
pendence including both behavioural and pharmacologi-
cal interventions [2]. Methadone maintenance therapy 
(MMT) has become a treatment of choice for chronic opi-
oid-dependent patients who cannot achieve abstinence. 
It has been shown that MMT can reduce heroin use, risk 
of HIV transmission, mortality, and crime [3]. However, 
MMT have limited effectiveness for some patients due to 
a variety of pharmacological and individual factors, while 
long-term methadone use can cause damage to the nerves, 
liver and cardiovascular system. This has led to the devel-
opment of alternative forms of maintenance treatments 
[4].
Oxytocin (OT) is a neuropeptide that is produced by 
the hypothalamus and plays an important role in re-
ward, social affiliation and bonding, associative learn-
ing, memory and stress responses [5, 6]. There is now 
strong evidence that OT is a possible candidate for the 
treatment of maladaptive processes associated with ad-
diction [7]. OT inhibits opioid tolerance [8], reduces 
opiates self-administration and decreases craving and 
stress response in marijuana dependent individuals [9]. 
A negative relationship between plasma OT levels and 
novelty seeking and increased negative affect and stress 
in different types of drug abuse have also been demon-
strated [10, 11]. Abstinent heroin-dependent patients 
experience negative affective state characterized by 
dysphoria, irritability, anxiety, as well as abnormal 
stress reactivity that drives drug seeking behaviours. 
These patients show elevated stress reactivity during 
withdrawal syndrome, which is related to heightened 
craving and symptoms of withdrawal [12]. Indeed, the 
activation of the hypothalamic-pituitary-adrenocorti-
cal axis and the elevated cortisol levels have been re-
ported during opioid withdrawal syndromes, while 
opioid agonist administration reduced cortisol secre-
tion, craving scores and amygdala activity in heroin-
dependent patients [13]. Furthermore, dehydroepian-
drosterone sulphate (DHEAS) may buffer the effects of 
cortisol and play a role in the resilience and in success-
ful adaptation to the stress. Cortisol and DHEAS and 
especially cortisol/DHEAS ratio are assaying as neuro-
adaptive stress hormones to predict health outcome 
[14, 15]. Given the established strong link between 
stress, drug use and relapse as along with the known 
dysregulation of hypothalamic pituitary adrenal (HPA) 
axis activity associated with substance-use disorders 
[16], the effects of OT on the stress system have re-
ceived a lot of attention. Therefore, the current study 
was designed to evaluate the acute effect of OT admin-
istration on withdrawal, craving, anxiety scores, and 
neuroadaptive stress hormones levels in the male her-
oin-dependent individuals.
Methods
Trial Design and Participants
This randomized, double-blind placebo-controlled clinical 
trial was registered in the Iranian website for registration of clin-
ical trials as http://www.irct.ir: IRCT (2015103024792N1). This 
research was carried out in accordance with the Declaration of 
Helsinki and received approval from the Ethics Committee of 
Kashan University of Medical Sciences (KAUMS). The partici-
pants were recruited from an inpatient treatment centre of (Be-
hzisti Addiction Rehabilitation Center, Isfahan, Iran), between 
December 2016 and March 2017. The participants (58 males) 
were selected by trained staff at the clinic following a blindness 
method. Due to the inadequacy of female heroin-dependent pa-
tients (only 4), the trial was carried out with only male patients 
referred to the centre. During a distinctive period of time (6–9 
days from abstinence), the subjects were prevented from taking 
any kind of illicit drugs including narcotic medicines. Only those 
participants who met the DSM-IV criteria for heroin dependence 
were selected. The participants were 20–60 years old. Exclusion 
criteria included other current substance abuse or dependence 
along with use of any psychoactive medication or medication 
known to alter HPA axis function. Drug urine tests were carried 
out to ensure that the subjects remained drug-free during the ex-
periment. The procedure was fully described for each subject be-
fore starting the project and written informed consent was ob-
tained [17].
Randomization
The subjects were assigned randomly to the treatment condi-
tion via a computer-generated random number by the aid of a 
trained staff at the clinic blindly.
Laboratory Procedures
An indwelling catheter was inserted at least 3 h before the 
sampling at 7 a.m. on the test day. The first cortisol and DHEAS 
blood sample were collected at 10 a.m. and then heroine with-
drawal symptom was measured using the Clinical Opioid With-
drawal Scale [18]. The craving scores were assessed by Visual 
Analogue Scale [19] and Desire for Drug Questionnaire [20], 
while the anxiety was evaluated by Hamilton checklist [21]. Bas-
al cortisol and DHEAS levels were assessed using a competitive 
immunoanalysis method on the COBAS E411 device. Referent 
intervals for morning cortisol and DHEAS were 138–690 nmol/L 
and 3–11 μmol/L respectively. The participants were provided 
with a light lunch. Then, medication was provided by the manu-
facturer of intranasal OT spray purchased from Novartis, Swit-
zerland and the placebo spray (normal saline) purchased from 
Raha Company, Iran. At 13: 15 p.m., 40 IU of OT or normal saline 
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was administered intranasally according to the previous studies 
[22, 23]. The participants were tested cue-induced craving task at 
14 p.m. The task was a pictorial design consisted of heroin-relat-
ed stimuli (heroine, pack, lighter, foil, heroine smoking, meeting 
a drug-using peer, watching others preparing and smoking) and 
neutral stimuli [24, 25]. At 14: 15 p.m., the task was completed. 
Withdrawal, craving and anxiety measurements were assessed 
again and then cortisol and DHEAS blood samples were collect-
ed from the participants at 30 and 60 min after the commence-
ment of the task.
Statistical Analysis
To establish the normal distribution of the variables, the Kol-
mogorov-Smirnov test was used. The analyses were carried out 
based on the intention-to-treat protocol. Demographic, clinical 
and biological variables between the case and control groups were 
compared using the independent sample t test and 1-way repeated 
measures analysis of variance respectively. Differences in the pro-
portions were assessed by the chi square test. Data is presented as 
mean ± SD or as median. The cortisol/DHEAS ratio was calcu-
lated as cortisol/DHEAS (* 100).
Results
Demographics
A total of 68 individuals were interviewed and assessed 
for the study participation. The reasons for the study ex-
clusion were medical issues (n = 5) and inability to pro-
vide a negative urine drug screen (n = 5). Therefore, this 
clinical trial was conducted on 58 male heroine addicted 
patients allocated to receive intranasal OT (single dose; 
40 IU, n = 29) or placebo (n = 29) randomly. During the 
treatment phase of the study, 4 patients from the control 
and 3 patients from the treatment groups could not com-
plete the trail (Fig. 1). Finally, our analysis sample includ-
ed 51 participants (OT [n = 27] and placebo [n = 24]). The 
mean age of the participants was 33.8 years (SD ± 8.8 
years). There were no significant differences between the 
2 groups in terms of demographic information such as 
marital status and educational level (Table 1).
The Effects of OT on Withdrawal, Craving and 
Anxiety Scores
As shown in Table 2, intranasal administration of a 
single dose of OT significantly improved Desire for Drug 
Questionnaire (–17.16 ± 4.36 vs. 3.51 ± 1.24 p < 0.001) 
and Visual Analogue Scale (–8.42 ± 3.86 vs. 2.1 ± 5.11 p < 
0.005) as craving scores. In addition, the acute adminis-
tration of OT significantly reduced the withdrawal symp-
tom as measured by Clinical Opioid Withdrawal Scale 
(–10.45 ± 2.99 vs. 2.45 ± 2.71 p < 0.001). However, OT 
therapy did not significantly affect the mean differences 
of the anxiety scores compared with the placebo group 
(–9.12 ± 1.89 vs. –6.39 ± 1.05 p < 0.11).
Assessed for eligibility (n = 68)
Excluded (n = 10)
- Medical issue (n = 5)
- Positive urine drug test (n = 5)
Randomized (n = 58)
Allocated to control
(n = 29)
Lost to follow-up due to
personal reasons
(n = 3)
Lost to follow-up due to
personal reasons
(n = 4)
Analyzed
(n = 3)
Analyzed
(n = 25)
Allocated to invention
(n = 29)
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Fig. 1. Summary of the patient flow dia-
gram.
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The Effects of OT on Stress-Related Hormones
The assessment of the serum cortisol level in the baseline 
did not show any significant difference between the control 
and the OT groups (20.28 ± 1.34 vs. 19.81 ± 2.38 µg/dL). The 
cortisol levels at 30 and 60 min after the stress test were 
21.21  ± 1.51 and 22.34 ± 1.40 in the control group and 
16.14 ± 1.57 and 15.21 ± 2.22 in the OT treatment group 
(Fig.  2). These results demonstrated that in comparison 
with the placebo group, the OT treatment significantly de-
creased serum cortisol level (p value < 0.01). The baseline 
DHEAS levels were 311.15 ± 12.69 and 312.69 ± 10.33 in the 
control and the OT group respectively. The DHEAS levels 
in 30 and 60 min after the stress test were 306.46 ± 10.45 vs. 
314.47 ± 9.52 and 308.22 ± 11.06 vs. 317.53 ± 10.63 (Fig. 3). 
Results showed that there were no significant differences in 
DHEAS levels between the control and the treatment 
groups (p value = 0.133). However, as shown in Figure 4, the 
Cortisol/DHEAS ratio at 60 min after the stress test showed 
a significant difference (p value < 0.05) between the placebo 
(6.89 ± 0.84) and the OT groups (4.28 ± 0.81; Fig. 4).
Table 1. General characteristics of the study participants
Character Oxytocin group 
(n = 29)
Placebo group 
(n = 29)
p value
Age, years 32.81±8.6 33.58±9.1 0.759
Marital status, n (%)
0.678
Permanent marriage 12 (44.4) 7 (29.2)
Single/never married 12 (44.4) 13 (54.2)
Separated/but not divorce 1 (3.7) 2 (8.3)
Divorced 2 (7.4) 2 (8.3)
Educational status, n (%)
0.248
Illiterate 3 (11.1) 2 (8.3)
Elementary 5 (18.1) 1 (4.2)
Primary 7 (25.9) 9 (37.5)
High school 9 (33.3) 9 (37.5)
College 3 (11.1) 1 (4.2)
BSc 0 (0) 2 (8.3)
Data are means ± SD obtained from chi-square test and Mann-Whitney and t test.
Table 2. Means ± SD of craving scores; DDQ and VAS, COWS, and anxiety at baseline and after the oxytocin 
therapy in heroin-dependent patients. p values show the differences between after and before the study in each 
group and result from the paired t test
Variables Groups Before  
intervention,  
mean ± SD
After  
intervention,  
mean ± SD
Mean  
differences,  
mean ± SD
p value
DDQ Placebo 38.18±3.12 41.69±2.88 3.51±1.24 0.001
Oxytocin 35.95±5.33 18.79±3.08 –17.16±4.36
VAS Placebo 32.25±3.69 34.35±5.09 2.1±5.11 0.005
Oxytocin 32.50±5.75 24.08±5.38 –8.42±3.86
COWS Placebo 28.04±2.46 30.59±3.18 2.45±2.71 0.001
Oxytocin 29.83±4.61 19.37±4.26 –10.45±2.99
Anxiety Placebo 13.82±1.47 7.43±1.05 –6.39±1.05 0.11
Oxytocin 14.45±2.45 5.33±1.11 –9.12±1.89
DDQ, Desire for Drug Questionnaire; VAS, Visual Analog Scale; COWS, Clinical Opioid Withdrawal Scale.
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Discussion
To our knowledge, the present study is the first ran-
domized, double-blind placebo-controlled clinical trial 
on the effects of OT on withdrawal, craving and stress 
response in heroin-dependent patients. In this research, 
intranasal administration of OT (single dose; 40 IU) im-
proved withdrawal symptoms, craving, cortisol level and 
cortisol/DHEAS ratio in the therapeutic group.
Numerous preclinical researches on the effects of OT 
on opioid-related behaviour have been done. Peripheral 
administration of OT has been shown to inhibit the de-
velopment of the tolerance and withdrawal to opioids. 
This effect seems to be centrally mediated ([7, 26] for re-
view). The mechanisms by which the OT changes the be-
havioural response to opioids are about to be understood. 
It has been shown that chronic morphine treatment in-
hibits OT synthesis in rats with a decrease in the supra-
optic nucleus and nucleus accumbens and an increase in 
the ventral tegmentum area and locus ceroleus [27]. Also, 
repeated morphine administration has enhanced the OT 
receptor binding in the olfactory nuclei, piriform cortex, 
septum and amygdala, while it has decreased the OT pep-
tide level in the hypothalamus. Administration of exog-
enous OT may reverse these changes in OT synthesis and 
receptors and this might translate to reversal of addictive 
behaviour [28].
Recent studies indicate that social attachments protect 
against addiction and health consequences of stress, 
whereas drug abuse and chronic stress can undermine 
social attachment [29, 30]. Indeed, negative social experi-
ences generally increase the vulnerability to drug abuse, 
while the development of strong social attachments, in-
cluding parent-offspring and adult pair bonding may 
buffer substance abuse [31]. It is suggested that OT in-
creases resilience against addiction and stress through the 
interaction with the central dopaminergic, serotonergic 
and the endogenous opioid system. This is done by fa-
cilitating the process of social bonding and attachment-
related information and its consolidation in internal 
working models. Thus, it contributes to promoting a shift 
from novelty seeking towards preference of social famil-
iarity through the cortical route [32]. The increasing body 
of evidence shows that stress exposure is an important 
contributing factor to drug dependence and suggests that 
cortisol release induced by stress of withdrawal, increases 
drug reinforcement. Our clinical data suggest that the OT 
may be useful to reduce craving and withdrawal symp-
toms through its effects on the HPA axis and attenuating 
stress-related physiological and subjective response [16]. 
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Our results indicate that OT does not affect subjective 
self-reporting of anxiety. Lack of effect on subjective 
stress may be attributable to inefficient OT’s dose or to 
the method used to assess stress (i.e., reliance on a blood 
venipuncture instead of salivary sample).
The present data demonstrates that intranasal OT de-
creased the serum cortisol level and improved the cortisol/
DHEAS ratio, which has been proved to be a reliable pre-
dictor for health and stress. These findings are in agree-
ment with the previous finding. It has been shown that 
intranasal OT significantly increased positive communi-
cation behaviour and reduced salivary cortisol levels dur-
ing the couple conflict discussion compared with the pla-
cebo [33]. It has also been shown that exogenous OT ad-
ministration has a boosting effect on the baseline activity 
of the brain OT system by raising brain OT levels [34, 35]. 
OT has been suggested to reduce HPA axis activation dur-
ing the stress. It has been shown that the activation of the 
OT receptor in the paraventricular nucleus delays the tran-
scription of the gene-encoding corticotropin-releasing 
factor, which is the main regulator of the stress response 
[36]. Molecular studies have shown localized OT receptors 
in the mesolimbic dopamine reward circuit, including the 
amygdala, the nucleus accumbens, the ventral tegmental 
area, and the corticotrophin-releasing factor stress sys-
tems [37]. OT and DHEAS are thought to influence central 
dopamine release considering the fact that the dopamine 
plays a major role in drug-induced reward. It is possible 
that OT administration also reduces craving and with-
drawal-induced stress through interaction with the meso-
corticolimbic dopaminergic system and other neurotrans-
mitter systems involved in addiction [38]. It is a fact that 
OT itself does not have rewarding effects and makes it a 
potential adjunct treatment for heroin addiction [39].
Our study showed that intranasal OT reduced craving 
and withdrawal scores but did not change anxiety signifi-
cantly in the heroin users during the abstinence. Also, the 
positive effects of OT on stress-related hormones may be 
involved in this effect of OT. Overall, this study suggest 
that OT may play a role in the attenuation of craving, with-
drawal symptom in heroin-dependent patients, and can be 
considered a new potential treatment for heroin addiction.
Limitation
The relatively small number of the subjects enrolled in 
this study requires that our results be considered prelim-
inary. Future studies of considerably larger sample size 
will be necessary to adequately test the validity of our 
findings. The long-term intervention might lead to better 
effects of OT. Finally, all participants were male and the 
current results need to be replicated in female groups.
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